Phase I trial of KX 02 in Chinese patients with brain tumours.
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs KX 02 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Xiangxue Pharmaceutical
- 24 May 2017 According to an Athenex media release, its partner, Guangzhou Xiangxue Pharmaceutical Co. Ltd., (Xiangxue) has received the Chinese FDA Investigational New Drug (IND) approval to begin clinical trials for KX-02 tablet for glioblastoma in May 2017 under the Class 1 New Drug Regulation in China.
- 30 Dec 2014 New trial record